Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · January 01, 2024

Atezolizumab Monotherapy vs Chemotherapy for Untreated Locally Advanced or Metastatic Urothelial Carcinoma

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
Lancet Oncol 2023 Dec 12;[EPub Ahead of Print], A Bamias, ID Davis, MD Galsky, JÁ Arranz, E Kikuchi, E Grande, XG Del Muro, SH Park, U De Giorgi, B Alekseev, M Mencinger, K Izumi, FA Schutz, J Puente, JR Li, S Panni, M Gumus, M Özgüroğlu, S Mariathasan, Y Poloz, F Bene-Tchaleu, C Lee, S Bernhard, M De Santis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading